Immunovant, Inc.

IMVT

NASDAQHealthcareBiotechnology

在 GoAI 中打开

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

48/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

Expensive

动量

Gaining

情绪

Mixed

风险韧性

Moderate Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Eric Venker
上市以来: 2019年6月21日
雇员: 315

市场位置

成交量: 84.66万; 0.52× 平均值
平均成交量: 163.28万; 日均成交量
市值: 91.58亿 USD
贝塔: 0.81; 市场参考 1

财务数据

财务快照

财务健康

奥特曼 Z 分数: 42.76
皮奥特罗斯基 F 分数: 3 共 9 个

财报历史与展望

最新财年每股收益: -2.77; 2026财年
最新财年收入: 0 USD; 2026财年
下一财年每股收益共识: -2.93; 2027财年 · 9位分析师
下一财年收入共识: 664.44万 USD; 2027财年 · 9位分析师

年度每股收益趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期

年度营收趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$40.00

下跌空间 9.85%

过去 12 个月12个月预测

价格历史记录不可用

最高：US$40.00平均的：US$40.00最低：US$40.00

近期分析师行动

12 机构

IMVT 消息

prnewswire.com2026年8月19日

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to…

阅读源码

defenseworld.net2026年8月18日

Immunovant (NASDAQ:IMVT) Sets New 12-Month High – Still a Buy?

Shares of Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $43.89 and last traded at $43.71, with a volume of 1216514 shares.…

阅读源码

seekingalpha.com2026年8月6日

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

阅读源码

marketbeat.com2026年8月6日

Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts…

阅读源码

zacks.com2026年8月6日

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

阅读源码

globenewswire.com2026年8月6日

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat…

阅读源码